Hugel Inc 2023 AR2
The report highlights Hugel's performance in 2023, achieving a record consolidated revenue of KRW 320 billion and an operating profit of KRW 118 billion. The company solidified its position as the leading medical aesthetics brand in Korea while expanding its global footprint, becoming the first Korean botulinum toxin company to enter the top three global markets of the US, China, and Europe. Hugel also advanced its sustainability initiatives, obtaining ISO 14001 and ISO 45001 certifications, and received the Minister of Employment and Labor Award for its industrial accident prevention efforts.
Company: Hugel Inc
Sector: Health Care
Country: South Korea
Year: 2023
Type: AR2
Pages: 62
Hugel Inc
Annual Report
The report highlights Hugel's performance in 2023, achieving a record consolidated revenue of KRW 320 billion and an operating profit of KRW 118 billion. The company solidified its position as the leading medical aesthetics brand in Korea while expanding its global footprint, becoming the first Korean botulinum toxin company to enter the top three global markets of the US, China, and Europe. Hugel also advanced its sustainability initiatives, obtaining ISO 14001 and ISO 45001 certifications, and received the Minister of Employment and Labor Award for its industrial accident prevention efforts.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Employees